Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome
- Conditions
- Diarrhea-predominant Irritable Bowel Syndrome
- Interventions
- Drug: PlaceboDrug: Tong-Xie-Yao-Fang
- Registration Number
- NCT02538692
- Lead Sponsor
- Chengdu University of Traditional Chinese Medicine
- Brief Summary
The purpose of this study is to test the efficacy and safety of a traditional Chinese medication Tong-Xie-Yao-Fang for patients with diarrhea-predominant irritable bowel Syndrome (IBS-D).
- Detailed Description
Participants: The sample size of this trial is 118, to test an odds ratio of 3.5 at a significance of 0.05 and power of 0.8.
Intervention: Tong-Xie-Yao-Fang versus placebo Data collection: Standard operation procedure will be developed for how to interviewing the participants, how to use the IBS diary, how to enter the data into the electronic case report forms.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
- Being diagnosed as IBS according to the Rome III criteria;
- Diarrhea was present for at least 75% of the time;
- With a TCM differentiation as "liver stagnation and spleen defficiency"
- Had a colonoscopy within a year to rule out other bowel diseases.
- Organic gastrointestinal disease, such as colorectal cancer, inflammatory bowel disease, advanced colonic polyp;
- Had gastrointestinal surgery within a year;
- Used durgs that affect gastrointestinal motility;
- Had psychological disorder;
- Serious disease in other system, which may bias the outcome measures.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules. Tong-Xie-Yao-Fang Tong-Xie-Yao-Fang Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
- Primary Outcome Measures
Name Time Method the proportion of patients who had adequate relief of global IBS-D symptoms for at least 2 of the 4 weeks. 4 weeks after initiation of treatment
- Secondary Outcome Measures
Name Time Method An visual scale rating the degree of IBS-D symptoms baseline(week 0), week 4, week 8, week 12 The scale ranges from 0 to 10. The score 0 indicates the mildest degree, while the 10 indicates the most serious degree.
Stool frequency per week baseline(week 0), week 4, week 8, week 12 Proportion of adverse events week 4
Trial Locations
- Locations (1)
Teaching Hospital of Chengdu University of TCM
🇨🇳Chengdu, Sichuan, China